Simplex Trading
ALNY icon

Simplex Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Simplex Trading’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.59M Buy
16,900
+4,200
+33% +$1.43M ﹤0.01% 1041
2025
Q4 		$5.05M Sell
12,700
-4,400
-26% -$1.95M ﹤0.01% 1255
2025
Q3 		$7.8M Buy
17,100
+3,400
+25% +$1.38M ﹤0.01% 1129
2025
Q2 		$4.47M Sell
13,700
-18,000
-57% -$4.98M ﹤0.01% 1444
2025
Q1 		$8.56M Buy
31,700
+4,200
+15% +$1.08M 0.01% 971
2024
Q4 		$6.47M Sell
27,500
-10,400
-27% -$2.74M ﹤0.01% 1295
2024
Q3 		$10.4M Sell
37,900
-50,500
-57% -$13.1M 0.01% 1009
2024
Q2 		$21.5M Sell
88,400
-64,800
-42% -$10.2M 0.01% 584
2024
Q1 		$22.9M Buy
153,200
+102,500
+202% +$17.1M 0.01% 627
2023
Q4 		$9.7M Buy
50,700
+27,600
+119% +$4.7M 0.01% 1102
2023
Q3 		$4.09M Buy
23,100
+200
+0.9% +$38.2K ﹤0.01% 1485
2023
Q2 		$4.35M Sell
22,900
-13,900
-38% -$2.76M ﹤0.01% 1409
2023
Q1 		$7.37M Sell
36,800
-14,900
-29% -$3.13M 0.01% 1061
2022
Q4 		$12.3M Buy
51,700
+32,200
+165% +$6.87M 0.01% 760
2022
Q3 		$3.9M Sell
19,500
-600
-3% -$114K ﹤0.01% 1382
2022
Q2 		$2.93M Sell
20,100
-11,200
-36% -$1.59M ﹤0.01% 1517
2022
Q1 		$5.11M Sell
31,300
-5,900
-16% -$899K ﹤0.01% 1228
2021
Q4 		$6.31M Buy
37,200
+11,500
+45% +$2.14M 0.01% 1060
2021
Q3 		$4.36M Hold
25,700
– – ﹤0.01% 1318
2021
Q2 		$4.36M Buy
25,700
+25,664
+71,289% +$3.76M ﹤0.01% 1309
2021
Q1 		$508K Sell
36
-188
-84% -$28.3K ﹤0.01% 3345
2020
Q4 		$2.91M Sell
224
-116
-34% -$15.5K ﹤0.01% 1414
2020
Q3 		$4.95M Buy
340
+163
+92% +$23.2K 0.01% 874
2020
Q2 		$2.62M Sell
177
-387
-69% -$52.2K ﹤0.01% 1295
2020
Q1 		$6.14M Buy
564
+81
+17% +$9.35K 0.01% 600
2019
Q4 		$5.56M Sell
483
-32
-6% -$3.19K 0.01% 735
2019
Q3 		$4.14M Buy
515
+238
+86% +$18.8K 0.01% 829
2019
Q2 		$2.01M Buy
277
+56
+25% +$4.3K 0.01% 1310
2019
Q1 		$2.06M Sell
221
-72
-25% -$6.02K 0.01% 1350
2018
Q4 		$2.14M Sell
293
-323
-52% -$24.8K 0.01% 1045
2018
Q3 		$5.39M Buy
616
+405
+192% +$40.7K 0.02% 581
2018
Q2 		$2.08M Buy
211
+50
+31% +$4.96K 0.01% 1098
2018
Q1 		$417K Sell
161
-121
-43% -$15.6K 0.02% 806
2017
Q4 		$651K Sell
282
-350
-55% -$44K 0.03% 583
2017
Q3 		$1.71M Buy
632
+298
+89% +$25.4K 0.07% 226
2017
Q2 		$313K Buy
334
+248
+288% +$15.8K 0.01% 923
2017
Q1 		$60K Sell
86
-142
-62% -$6.56K ﹤0.01% 2194
2016
Q4 		$28K Buy
228
+72
+46% +$3.02K ﹤0.01% 2716
2016
Q3 		$42K Sell
156
-6
-4% -$423 ﹤0.01% 2238
2016
Q2 		$33K Buy
162
+106
+189% +$6.68K ﹤0.01% 2427
2016
Q1 		$16K Sell
56
-133
-70% -$8.84K ﹤0.01% 2987
2015
Q4 		$46K Buy
189
+13
+7% +$1.21K ﹤0.01% 1974
2015
Q3 		$23K Buy
176
+169
+2,414% +$18.8K ﹤0.01% 2638
2015
Q2 		$7K Sell
7
-24
-77% -$2.87K ﹤0.01% 3333
2015
Q1 		$15K Buy
31
+7
+29% +$709 ﹤0.01% 2536
2014
Q4 		$32K Buy
+24
New +$2.22K ﹤0.01% 1691

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading's ALNY Position: Q2 2025 in Review

Simplex Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 6,704 shares — an estimated $1.86M sold.

Simplex Trading first reported a position in ALNY in Q4 2014 and held it in 26 quarters. The position peaked at $2.75M in Q1 2023. 653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Simplex Trading reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Simplex Trading sold 6,704 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $1.86M.
  • Simplex Trading first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 26 quarters.
  • Simplex Trading's Alnylam Pharmaceuticals position peaked at $2.75M in Q1 2023.
  • 653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.